Paradoxically, while antibiotics targeting pathogenic bacteria may enhance PD-1 inhibitor efficacy in hepatobiliary cancers (107), prolonged antibiotic use correlates with reduced survival in HCC patients receiving anti-PD-1 therapy, likely due to microbiota disruption (108). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.